Antibody Information

General Information of This Antibody
Antibody ID
ANI0XVENZ
Antibody Name
Human ITGB6 SGN-B6A mAb
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG
Antigen Name
Integrin beta-6 (ITGB6)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-B6A [Phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with metastatic or unresectable solid tumors.
Administration Dosage
30 patients in Q1W (0.80, 1.00, and 1.20 mg/kg); 18 patients in 2Q3W (1.20 or 1.25 mg/kg).
Related Clinical Trial
NCT Number NCT04389632  Clinical Status Phase 1/2
Clinical Description
A phase 1 study of SGN-B6A in advanced solid tumors.
References
Ref 1 Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021 39:15_suppl, 2631-2631.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.